The Food and Drug Admisntartion has issued mandatory recall orders for Kratom containing products amidst concerns they triggered a large outbreak of Salmonellosis. The recall essentially paints a clear picture of what LexaGene Holdings Inc. (OTCQB: LXXGF) (TSX-V:LXG)’s newly developed pathogen detection technology could play in future, in the identification of such deadly bacteria.
The FDA says after conducting a months-long investigation, it discovered high rates of Salmonella contamination in Kratom products. Food items contaminated with Salmonella is not a new phenomenon in the U.S. However, the primary concern is the amount of time it takes to identify the bacteria in items before they are shipped to consumers.
Early in the year, the U.S Centers for disease Control and Prevention identified an outbreak of illnesses due to salmonella. Investigations conducted by state and local health departments in coordination with the CDC found that a high proportion of ill people had consumed Kratom products either as capsules powders or herbal medicines.
Most Kratom that finds its way into the United States comes from Southeast Asia where it is grown and processed in problematic conditions that enhance the chances of widespread contamination with a foodborne pathogen. The Salmonella problem with Kratom has been ongoing for a year because of a lack of a clear identification mechanism for pathogens.
Lexagene Pathogen Detection Technology
In comes Lexagene, which has developed a first of its kind pathogen detection technology capable of over 22 pathogens in under an hour including some of the most dangerous bacteria. The Biotechnology Company believes its easier and less expensive technology is a better bacteria detection solution given that it can identify E.coli in addition to salmonella.
The technology is specifically designed for healthcare providers as well as food safety officers as it can process up to six samples at a time and provide results in under an hour. The biotechnology company is planning to demonstrate the prototype first hand so that people can appreciate its impact on the food industry
“Over the next several months, we will continue to optimize the performance of the instrument and equip it with reagents to detect more diseases such as Salmonella and Listeria. Once we finalize our pathogen-detection panel, we’ll begin processing samples to demonstrate our advantages over standard testing procedures,” said CEO Jack Regan.
Lexagene expects the technology to reduce chances of shipping contaminated food items significantly. In addition, it should provide the company with exposure to the $13.5 billion food safety industry that has been struggling with pathogens for decades.
The biotechnology company also plans to apply the technology to help healthcare providers diagnose patients. Currently, health care providers collect samples from patients and ship them to an offsite laboratory, a process that usually takes days to send and receive results.
With the use of Lexagene, technology healthcare providers will now be able to identify the presence of antibiotic resistance bacteria in under an hour. The providers will also be able to treat patients with more targeted therapies while they are still in the facility. The biotechnology company expects the technology to be the world’s first easy-to-use open access rapid pathogen detection system.
RESAAS Signs Joint Venture With San Francisco Title Technology Company to Tokenize every Property in the United States, backed by Investment Bank US Capital Global to Raise Up To $7 million USD
BREAKING NEWS UPDATE: July 31, 2018 – RESAAS Services Inc. (TSX.V: RSS, OTCQX: RSASF) RESAAS Signs Joint Venture With San Francisco Title...